The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.
Ebselen, Disulfiram, Carmofur, PX-12, Tideglusib, and Shikonin Are Nonspecific Promiscuous SARS-CoV-2 Main Protease Inhibitors
Open accessAbstract
Among the drug targets being investigated for SARS-CoV-2, the viral main protease (Mpro) is one of the most extensively studied. Mpro is a cysteine protease that hydrolyzes the viral polyprotein at more than 11 sites. It is highly conserved and has a unique substrate preference for glutamine in the P1 position. Therefore, Mpro inhibitors are expected to have broad-spectrum antiviral activity and a high selectivity index. Structurally diverse compounds have been reported as Mpro inhibitors. In this study, we investigated the mechanism of action of six previously reported Mpro inhibitors, ebselen, disulfiram, tideglusib, carmofur, shikonin, and PX-12, using a consortium of techniques including FRET-based enzymatic assay, thermal shift assay, native mass spectrometry, cellular antiviral assays, and molecular dynamics simulations. Collectively, the results showed that the inhibition of Mpro by these six compounds is nonspecific and that the inhibition is abolished or greatly reduced with the addition of reducing reagent 1,4-dithiothreitol (DTT). Without DTT, these six compounds inhibit not only Mpro but also a panel of viral cysteine proteases including SARS-CoV-2 papain-like protease and 2Apro and 3Cpro from enterovirus A71 (EV-A71) and EV-D68. However, none of the compounds inhibits the viral replication of EV-A71 or EV-D68, suggesting that the enzymatic inhibition potency IC50 values obtained in the absence of DTT cannot be used to faithfully predict their cellular antiviral activity. Overall, we provide compelling evidence suggesting that these six compounds are nonspecific SARS-CoV-2 Mpro inhibitors and urge the scientific community to be stringent with hit validation.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A pneumonia outbreak associated with a new coronavirus of probable bat origin
Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., et al. (2020) · Nature · doi:10.1038/s41586-020-2012-7 · Cited by 21,969
Hoffmann, M., Kleine-Weber, H., Schroeder, S., Krüger, N., Herrler, T., Erichsen, S., Schiergens, T. S., Herrler, G., Wu, N.-H., Nitsche, A., et al. (2020) · Cell · doi:10.1016/j.cell.2020.02.052 · Cited by 20,286
The proximal origin of SARS-CoV-2
Andersen, K. G., Rambaut, A., Lipkin, W. I., Holmes, E. C., & Garry, R. F. (2020) · Nature Medicine · doi:10.1038/s41591-020-0820-9 · Cited by 5,081
Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
Jin, Z., Du, X., Xu, Y., Deng, Y., Liu, M., Zhao, Y., Zhang, B., Li, X., Zhang, L., Peng, C., et al. (2020) · Nature · doi:10.1038/s41586-020-2223-y · Cited by 4,358
Cell entry mechanisms of SARS-CoV-2
Shang, J., Wan, Y., Luo, C., Ye, G., Geng, Q., Auerbach, A., & Li, F. (2020) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2003138117 · Cited by 3,142
Zhang, L., Lin, D., Sun, X., Curth, U., Drosten, C., Sauerhering, L., Becker, S., Rox, K., & Hilgenfeld, R. (2020) · Science · doi:10.1126/science.abb3405 · Cited by 2,895
Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
Sheahan, T. P., Sims, A. C., Graham, R. L., Menachery, V. D., Gralinski, L. E., Case, J. B., Leist, S. R., Pyrc, K., Feng, J. Y., Trantcheva, I., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aal3653 · Cited by 1,571
Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
Dai, W., Zhang, B., Jiang, X.-M., Su, H., Li, J., Zhao, Y., Xie, X., Jin, Z., Peng, J., Liu, F., et al. (2020) · Science · doi:10.1126/science.abb4489 · Cited by 1,478
Self-citationLiu, C., Zhou, Q., Li, Y., Garner, L. V., Watkins, S. P., Carter, L. J., Smoot, J., Gregg, A. C., Daniels, A. D., Jervey, S., et al. (2020) · ACS Central Science · doi:10.1021/acscentsci.0c00272 · Cited by 1,297
Sheahan, T. P., Sims, A. C., Zhou, S., Graham, R. L., Pruijssers, A. J., Agostini, M. L., Leist, S. R., Schäfer, A., Dinnon, K. H., Stevens, L. J., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.abb5883 · Cited by 1,071
Marty, M. T., Baldwin, A. J., Marklund, E. G., Hochberg, G. K. A., Benesch, J. L. P., & Robinson, C. V. (2015) · Analytical Chemistry · doi:10.1021/acs.analchem.5b00140 · Cited by 1,000
Self-citationMa, C., Sacco, M. D., Hurst, B., Townsend, J. A., Hu, Y., Szeto, T., Zhang, X., Tarbet, B., Marty, M. T., Chen, Y., et al. (2020) · Cell Research · doi:10.1038/s41422-020-0356-z · Cited by 880
Self-citationA noncovalent class of papain-like protease/deubiquitinase inhibitors blocks SARS virus replication
Ratia, K., Pegan, S., Takayama, J., Sleeman, K., Coughlin, M., Baliji, S., Chaudhuri, R., Fu, W., Prabhakar, B. S., Johnson, M. E., et al. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0805240105 · Cited by 507
Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
Jin, Z., Zhao, Y., Sun, Y., Zhang, B., Wang, H., Wu, Y., Zhu, Y., Zhu, C., Hu, T., Du, X., et al. (2020) · Nature Structural & Molecular Biology · doi:10.1038/s41594-020-0440-6 · Cited by 426
Sacco, M. D., Ma, C., Lagarias, P., Gao, A., Townsend, J. A., Meng, X., Dube, P., Zhang, X., Hu, Y., Kitamura, N., et al. (2020) · Science Advances · doi:10.1126/sciadv.abe0751 · Cited by 385
Self-citationFreitas, B. T., Durie, I. A., Murray, J., Longo, J. E., Miller, H. C., Crich, D., Hogan, R. J., Tripp, R. A., & Pegan, S. D. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00168 · Cited by 290
Cathepsin L-selective inhibitors: A potentially promising treatment for COVID-19 patients
Liu, T., Luo, S., Libby, P., & Shi, G.-P. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107587 · Cited by 273
Disulfiram can inhibit MERS and SARS coronavirus papain-like proteases via different modes
Lin, M.-H., Moses, D. C., Hsieh, C.-H., Cheng, S.-C., Chen, Y.-H., Sun, C.-Y., & Chou, C.-Y. (2018) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.015 · Cited by 250
Evidence for Irreversible Inhibition of Glycogen Synthase Kinase-3β by Tideglusib
Domínguez, J. M., Fuertes, A., Orozco, L., del Monte-Millán, M., Delgado, E., & Medina, M. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.306472 · Cited by 246
Kim, Y., Liu, H., Galasiti Kankanamalage, A. C., Weerasekara, S., Hua, D. H., Groutas, W. C., Chang, K.-O., & Pedersen, N. C. (2016) · PLOS Pathogens · doi:10.1371/journal.ppat.1005531 · Cited by 238
Pedersen, N. C., Kim, Y., Liu, H., Galasiti Kankanamalage, A. C., Eckstrand, C., Groutas, W. C., Bannasch, M., Meadows, J. M., & Chang, K.-O. (2018) · Journal of Feline Medicine and Surgery · doi:10.1177/1098612x17729626 · Cited by 222
A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic
Funk, C. D., Laferrière, C., & Ardakani, A. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00937 · Cited by 201
Potential therapeutic use of ebselen for COVID-19 and other respiratory viral infections
Sies, H., & Parnham, M. J. (2020) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2020.06.032 · Cited by 172
A small-molecule antivirulence agent for treating Clostridium difficile infection
Bender, K. O., Garland, M., Ferreyra, J. A., Hryckowian, A. J., Child, M. A., Puri, A. W., Solow-Cordero, D. E., Higginbottom, S. K., Segal, E., Banaei, N., et al. (2015) · Science Translational Medicine · doi:10.1126/scitranslmed.aac9103 · Cited by 136
Paranjpe, A., Zhang, R., Ali‐Osman, F., Bobustuc, G. C., & Srivenugopal, K. S. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt366 · Cited by 121
Ebselen, a Small-Molecule Capsid Inhibitor of HIV-1 Replication
Thenin-Houssier, S., de Vera, I. M. S., Pedró-Rosa, L., Brady, A., Richard, A. S., Konnick, B., Opp, S., Buffone, C., Fuhrmann, J., Kota, S., et al. (2016) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02574-15 · Cited by 112
Molecular characterization of ebselen binding activity to SARS-CoV-2 main protease
Menéndez, C. A., Byléhn, F., Pérez-Lemus, G. R., et al. (2020) · Science Advances · doi:10.1126/sciadv.abd0345 · Cited by 108
Mukherjee, S., Weiner, W. S., Schroeder, C. E., Simpson, D. S., Hanson, A. M., Sweeney, N. L., Marvin, R. K., Ndjomou, J., Kolli, R., Isailović, D., et al. (2014) · ACS Chemical Biology · doi:10.1021/cb500512z · Cited by 95
Azad, G. K., Singh, V., Mandal, P., Singh, P. K., Golla, U., Baranwal, S., Chauhan, S., & Tomar, R. S. (2014) · FEBS Open Bio · doi:10.1016/j.fob.2014.01.002 · Cited by 92
2-[(1-Methylpropyl)dithio]-1H-imidazole inhibits tubulin polymerization through cysteine oxidation
Huber, K. D., Patel, P. M., Zhang, L., Evans, H., Westwell, A. D., Fischer, P. M., Chan, S. Y. T., & Martin, S. G. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0486 · Cited by 73
Musharrafieh, R. G., Ma, C., Zhang, J., Hu, Y., Diesing, J. M., Marty, M. T., & Wang, J. (2019) · Journal of Virology · doi:10.1128/jvi.02221-18 · Cited by 70
Self-citationStructural Basis for Inactivation of Giardia lamblia Carbamate Kinase by Disulfiram
Galkin, A. G., Kulakova, L., Lim, K., Chen, C. Z., Zheng, W., Turko, I. V., & Herzberg, O. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.553123 · Cited by 62
Interaction of ebselen with glutathione S-transferase and papain in vitro
Nikawa, T., Schuch, G., Wagner, G., & Sies, H. (1994) · Biochemical Pharmacology · doi:10.1016/0006-2952(94)90411-1 · Cited by 54
Enterovirus A71 DNA-Launched Infectious Clone as a Robust Reverse Genetic Tool
Tan, C. W., Tee, H. K., Lee, M. H. P., Sam, I., & Chan, Y. F. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162771 · Cited by 44
Inhibition of Urease by Disulfiram, an FDA-Approved Thiol Reagent Used in Humans
Díaz‐Sánchez, Á. G., ́Álvarez-Parrilla, E., Martı́nez-Martı́nez, A., Aguirre-Reyes, L. G., Orozpe-Olvera, J., Ramos-Soto, M., Núñez-Gastélum, J. A., Alvarado‐Tenorio, B., & la Rosa, L. A. D. (2016) · Molecules · doi:10.3390/molecules21121628 · Cited by 43
Goins, C. M., Dajnowicz, S., Thanna, S., Sucheck, S. J., Parks, J. M., & Ronning, D. R. (2017) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.7b00003 · Cited by 42
A Novel Capsid Binding Inhibitor Displays Potent Antiviral Activity against Enterovirus D68
Ma, C., Hu, Y., Zhang, J., Musharrafieh, R. G., & Wang, J. (2019) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.9b00284 · Cited by 38
Self-citationDevelopment of broad-spectrum enterovirus antivirals based on quinoline scaffold
Musharrafieh, R. G., Kitamura, N., Hu, Y., & Wang, J. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103981 · Cited by 37
Self-citationZhou, Q. A., Kato-Weinstein, J., Li, Y., Deng, Y., Granet, R., Garner, L. V., Liu, C., Polshakov, D. A., Gessner, C., & Watkins, S. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.0c00074 · Cited by 29
Ma, C., Hu, Y., Zhang, J., et al. (2020) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.0c00383 · Cited by 27
Self-citation
Cited by
Ma, C., Tan, H., Choza, J., Wang, Y., & Wang, J. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2021.10.026 · Cited by 86
Self-citationTan, H., Ma, C., & Wang, J. (2022) · Medicinal Chemistry Research · doi:10.1007/s00044-022-02903-0 · Cited by 21
Self-citationThe Promiscuity of Disulfiram in Medicinal Research
Cvek, B. (2023) · ACS Medicinal Chemistry Letters · doi:10.1021/acsmedchemlett.3c00450 · Cited by 21
DWV 3C Protease Uncovers the Diverse Catalytic Triad in Insect RNA Viruses
Yuan, X., & Kadowaki, T. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00068-22 · Cited by 5
Metadata
- Authors
- Ma, C., Hu, Y., Townsend, J. A., Lagarias, P. I., Marty, M. T., Kolocouris, A., & Wang, J.
- Venue
- ACS Pharmacology & Translational Science
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-10-09
- Volume
- 3
- Issue
- 6
- Pages
- 1265-1277
- ISSN
- 2575-9108 (ISSN-L)
- OpenAlex
- W3092541273
- Cited by
- 262
- References
- 40
- FWCI
- 5.43
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.